Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.73 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.73 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.73 |
| ▸ | NPY1R | P25929 | 3/20 | 0.65 |
| ▸ | NPY2R | P49146 | 3/20 | 0.65 |
| ▸ | NPY4R | P50391 | 3/20 | 0.65 |
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | MC5R | P33032 | 1/20 | 0.56 |
| ▸ | MC3R | P41968 | 1/20 | 0.56 |
| ▸ | MC1R | Q01726 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738308 | 1.00 | ERAP2 (0.73) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL29373777 | 0.93 | NPY1R (0.74) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL29390038 | 0.93 | NPY1R (0.67) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL29738307 | 0.92 | ERAP2 (0.63) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30165601 | 0.92 | ERAP2 (0.63) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL29426680 | 0.90 | NPY1R (0.68) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL29805135 | 0.90 | NPY1R (0.79) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL30797506 | 0.90 | NPY1R (0.79) | ERAP2ERAP1LNPEPNPY1RNPY2R | |
| SCHEMBL31253359 | 0.87 | ACE (0.64) | ERAP2ERAP1LNPEPACEECE1 | |
| SCHEMBL30659508 | 0.87 | ACE (0.64) | ERAP2ERAP1LNPEPACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818386-A | Biological peptide antibacterial mouthwash and preparation method and application thereof | 奥洁玛(北京)生物科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118878628-A | Efficient and stable self-assembled antibacterial peptide RW7 and preparation method and application thereof | 中国水产科学研究院黑龙江水产研究所 | 2024-11-01 | — | — | CN | claimed |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-119876085-A | Alpha-amino acid ester acyltransferase mutant and application thereof | 天津凯莱英生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-118878628-A | Efficient and stable self-assembled antibacterial peptide RW7 and preparation method and application thereof | 中国水产科学研究院黑龙江水产研究所 | 2024-11-01 | — | — | CN | disclosed |
| CN-117677302-A | Peptide compounds for flavor modulation | CJ第一制糖株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-116987141-A | Natural antibacterial peptide derived from fungi and application thereof | 深圳市第二人民医院(深圳市转化医学研究院) | 2023-11-03 | — | — | CN | disclosed |
| CN-116640819-B | Preparation method of alpha-amino acid lipid acyltransferase and application of alpha-amino acid lipid acyltransferase in dipeptide synthesis | 凯莱英生命科学技术(天津)有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116622795-B | Preparation method of L-amino acid ligase and application of L-amino acid ligase in dipeptide synthesis | 凯莱英生命科学技术(天津)有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116808282-A | Composite double-network hydrogel, preparation method and application | 湖南科技学院 | 2023-09-29 | — | — | CN | disclosed |
| CN-116640819-A | Preparation method of alpha-amino acid lipid acyltransferase and application of alpha-amino acid lipid acyltransferase in dipeptide synthesis | 凯莱英生命科学技术(天津)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116622795-A | Preparation method of L-amino acid ligase and application of L-amino acid ligase in dipeptide synthesis | 凯莱英生命科学技术(天津)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111617231-B | Uric acid-reducing and gout-resisting composition as well as preparation method and application thereof | 北京同仁堂健康药业股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | AJK BIOPHARMACEUTICAL LLC (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | ERAP2 1826/4885ERAP1 1237/4885LNPEP 212/4885 |
| US-20220289794-A1 | SYNTHETIC ANTIMICROBIAL PEPTIDES | VIP, HM13, NGLY1 | ERAP2 506/4885ERAP1 208/4885LNPEP 7/4885 |
| US-20260102461-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | MAX, CRYZ, STAMBP | ERAP2 2717/4885ERAP1 1672/4885LNPEP 460/4885 |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | MICA, IGSF11, TNFSF10 | ERAP2 3082/4885ERAP1 1388/4885LNPEP 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.